More accurate end-tidal CO2 monitoring compared to a nasal cannula.
Arete’s founders will be showcasing CapnoFlow, our innovative respiratory monitoring technology designed to help improve patient safety, support clinical decision-making, and advance the standard of care in a variety of healthcare environments.

Arete presents the only product on the market that adjusts to the three most common adult oral airway sizes and is equipped with designated ports for monitoring EtCO2, delivering oxygen, and suctioning.

Download our investment flyer and learn how Arete is revolutionizing the oral airway industry!
The global medical device industry is projected to exceed $600 billion in the coming years, driven by aging populations, the increasing prevalence of chronic diseases, and growing demand for innovative healthcare technologies. Arete is strategically positioned to capture market share with solutions designed to address unmet clinical needs, improve patient outcomes, and streamline healthcare delivery across a variety of care settings.
Arete's innovation pipeline is built on proprietary technologies developed through rigorous research, development, and clinical validation. The company focuses on creating medical devices that enhance patient outcomes while helping providers and payers reduce costs. Supported by a growing intellectual property portfolio and ongoing patent development efforts, Arete continues to advance solutions designed to meet evolving healthcare challenges.
Arete's competitive advantage stems from its commitment to patient-centered design, regulatory excellence, and strategic collaboration. Every device is engineered with a focus on usability, safety, and measurable clinical impact. The company's dedication to compliance and quality standards supports efficient regulatory pathways and market entry, while partnerships with healthcare providers, research institutions, and distribution organizations help accelerate adoption and expand market reach.
Arete has achieved key development milestones, including successful prototype validation and valuable early clinical feedback that has helped guide product refinement. The company has secured initial funding and grant support to advance growth initiatives, and its product pipeline continues to progress toward regulatory clearance and commercialization. These achievements demonstrate meaningful momentum and a clear path toward market expansion.
Arete's business model is designed to support scalable growth across multiple healthcare markets and geographic regions. In addition to device sales, the company is positioned to create recurring revenue opportunities through service agreements, strategic partnerships, and licensing arrangements. With a disciplined commercialization strategy and growing market demand, Arete is well positioned for long-term expansion and a clear path toward profitability.
Want to hear what actual clinicians are saying about Arete's industry disrupting line of oral airway devices? Take a look at recent testimonials below!
More accurate end-tidal CO2 monitoring compared to a nasal cannula.

Would recommend Arete's oral airway to other anesthesia providers.
